Kehong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kehong Chen has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Jia Chen
Department of Nephrology, Daping Hospital, Army Medical Center, Army Medical University, No. 10 Changjiang Road, Yuzhong District, Chongqing 400042, China; Chongqing Key Laboratory of Precision Diagnosis and Treatment for Kidney Diseases, No. 10 Changjiang Road, Yuzhong District, Chongqing 400042, China
5 shared publicationsJie Yang
Department of nephrology, Daping Hospital, Army Medical University
5 shared publicationsJingfang Wan
Department of nephrology, Daping Hospital, Army Medical University
4 shared publications- Yani He
Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China
4 shared publications Kaizhen Yv
Department of nephrology, Daping Hospital, Army Medical University
3 shared publicationsShihui Hou
Department of nephrology, Daping Hospital, Army Medical University
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1843381
Optimal prediction of peritoneal dialysis to hemodialysis transition: a penalized fine-gray model
Background: Traditional Cox proportional hazards models overestimate the risk of progression from peritoneal dialysis (PD) to hemodialysis (HD). This study aims to screen high-risk conversion populations using competing risk models. Methods: In this multicenter retrospective cohort study, we enrolled patients aged ≥16 years who were undergoing regular PD for >1 month; transition from PD to HD was the target event. When death was recognized as a competing event, we employed cause-specific proportional hazards and Fine-Gray models for multivariate analysis. A conventional LASSO-Cox model was also established for comparative purposes. Model performance was evaluated using time-dependent area under the curve (AUC) and C-index curves. The best model was identified to construct the cumulative incidence nomogram for PD to HD at the 3-, 6-, and 9-year time points. Results: We enrolled 700 valid samples that were randomly allocated at a ratio of 7:3 to the training ( n = 491) and test sets ( n = 209). The penalized Fine-Gray model was identified as the optimal model (AUC: 0.716, C-index: 0.662). Body mass index, history of peritonitis hospitalization, and nutrition-related parameters were identified as optimal predictors for transitioning from PD to HD. AUC values for the penalized Fine-Gray model at 3, 6, and 9 years were 0.675, 0.715, and 0.714, respectively. We constructed a nomogram for 3, 6, and 9 years based on the penalized Fine-Gray model, which demonstrated significant clinical utility. Conclusion: The penalized Fine-Gray model serves as the optimal choice for predicting the transition from PD to HD, and the nomogram constructed based on this model exhibits favorable clinical applicability.
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1843381
Open AccessOptimal prediction of peritoneal dialysis to hemodialysis transition: a penalized fine-gray model
Background: Traditional Cox proportional hazards models overestimate the risk of progression from peritoneal dialysis (PD) to hemodialysis (HD). This study aims to screen high-risk conversion populations using competing risk models. Methods: In this multicenter retrospective cohort study, we enrolled patients aged ≥16 years who were undergoing regular PD for >1 month; transition from PD to HD was the target event. When death was recognized as a competing event, we employed cause-specific proportional hazards and Fine-Gray models for multivariate analysis. A conventional LASSO-Cox model was also established for comparative purposes. Model performance was evaluated using time-dependent area under the curve (AUC) and C-index curves. The best model was identified to construct the cumulative incidence nomogram for PD to HD at the 3-, 6-, and 9-year time points. Results: We enrolled 700 valid samples that were randomly allocated at a ratio of 7:3 to the training ( n = 491) and test sets ( n = 209). The penalized Fine-Gray model was identified as the optimal model (AUC: 0.716, C-index: 0.662). Body mass index, history of peritonitis hospitalization, and nutrition-related parameters were identified as optimal predictors for transitioning from PD to HD. AUC values for the penalized Fine-Gray model at 3, 6, and 9 years were 0.675, 0.715, and 0.714, respectively. We constructed a nomogram for 3, 6, and 9 years based on the penalized Fine-Gray model, which demonstrated significant clinical utility. Conclusion: The penalized Fine-Gray model serves as the optimal choice for predicting the transition from PD to HD, and the nomogram constructed based on this model exhibits favorable clinical applicability.
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 16 (1) , 127-135
Dapagliflozin May Increase Ultrafiltration and Urine Volume in Nondiabetic Peritoneal Dialysis Patients: A Case Series Report
Introduction: Reduced ultrafiltration in peritoneal dialysis (PD) contributes to volume overload, increasing the risk of technique failure and patient mortality. The administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) has been shown to increase ultrafiltration volume in mice, suggesting its potential role in improving ultrafiltration. However, whether SGLT2i can improve ultrafiltration and increase urine volume in nondiabetic PD patients remains unclear. Case Presentation: We report 6 nondiabetic PD patients with a dialysis history of more than 3 months who received 10 mg of dapagliflozin once daily orally for 6 months, in addition to their conventional treatment regimens. After 6 months, clinically significant increases in ultrafiltration were observed (from 76.8 mL at baseline to 211.3 mL), and 5 patients showed increased urine volume (from 433.3 mL to 646.7 mL). The glucose concentration in the effluent dialysate was higher than that at baseline. No changes in peritoneal transport characteristics, estimated glomerular filtration rate, or residual renal creatinine clearance rate were observed at this point compared with baseline. No adverse effects, such as hypoglycemia or abnormal liver function, were reported in any of the patients. Conclusions: In this preliminary observation, dapagliflozin use was associated with increased ultrafiltration and urine volume in nondiabetic PD patients and presented a favorable safety profile. Further controlled studies are needed to confirm these preliminary findings.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 16 (1) , 127-135
Open AccessDapagliflozin May Increase Ultrafiltration and Urine Volume in Nondiabetic Peritoneal Dialysis Patients: A Case Series Report
Introduction: Reduced ultrafiltration in peritoneal dialysis (PD) contributes to volume overload, increasing the risk of technique failure and patient mortality. The administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) has been shown to increase ultrafiltration volume in mice, suggesting its potential role in improving ultrafiltration. However, whether SGLT2i can improve ultrafiltration and increase urine volume in nondiabetic PD patients remains unclear. Case Presentation: We report 6 nondiabetic PD patients with a dialysis history of more than 3 months who received 10 mg of dapagliflozin once daily orally for 6 months, in addition to their conventional treatment regimens. After 6 months, clinically significant increases in ultrafiltration were observed (from 76.8 mL at baseline to 211.3 mL), and 5 patients showed increased urine volume (from 433.3 mL to 646.7 mL). The glucose concentration in the effluent dialysate was higher than that at baseline. No changes in peritoneal transport characteristics, estimated glomerular filtration rate, or residual renal creatinine clearance rate were observed at this point compared with baseline. No adverse effects, such as hypoglycemia or abnormal liver function, were reported in any of the patients. Conclusions: In this preliminary observation, dapagliflozin use was associated with increased ultrafiltration and urine volume in nondiabetic PD patients and presented a favorable safety profile. Further controlled studies are needed to confirm these preliminary findings.
- Top Cited PapersOpen Access
- 30 July 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (8) , 116084
Protein lactylation of citrate synthase promotes the AKI-CKD transition by activating the NLRP3 inflammasome
- 30 July 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (8) , 116084
Top Cited PapersOpen AccessProtein lactylation of citrate synthase promotes the AKI-CKD transition by activating the NLRP3 inflammasome
- Open Access
- 2 January 2024
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 24 (1) , 1-11
Machine learning algorithms for the prediction of adverse prognosis in patients undergoing peritoneal dialysis
Background: An appropriate prediction model for adverse prognosis before peritoneal dialysis (PD) is lacking. Thus, we retrospectively analysed patients who underwent PD to construct a predictive model for adverse prognoses using machine learning (ML). Methods: A retrospective analysis was conducted on 873 patients who underwent PD from August 2007 to December 2020. A total of 824 patients who met the inclusion criteria were included in the analysis. Five commonly used ML algorithms were used for the initial model training. By using the area under the curve (AUC) and accuracy (ACC), we ranked the indicators with the highest impact and displayed them using the values of Shapley additive explanation (SHAP) version 0.41.0. The top 20 indicators were selected to build a compact model that is conducive to clinical application. All model-building steps were implemented in Python 3.8.3. Results: At the end of follow-up, 353 patients withdrew from PD (converted to haemodialysis or died), and 471 patients continued receiving PD. In the complete model, the categorical boosting classifier (CatBoost) model exhibited the strongest performance (AUC = 0.80, 95% confidence interval [CI] = 0.76–0.83; ACC: 0.78, 95% CI = 0.72–0.83) and was selected for subsequent analysis. We reconstructed a compression model by extracting 20 key features ranked by the SHAP values, and the CatBoost model still showed the strongest performance (AUC = 0.79, ACC = 0.74). Conclusions: The CatBoost model, which was built using the intelligent analysis technology of ML, demonstrated the best predictive performance. Therefore, our developed prediction model has potential value in patient screening before PD and hierarchical management after PD.
- 2 January 2024
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 24 (1) , 1-11
Open AccessMachine learning algorithms for the prediction of adverse prognosis in patients undergoing peritoneal dialysis
Background: An appropriate prediction model for adverse prognosis before peritoneal dialysis (PD) is lacking. Thus, we retrospectively analysed patients who underwent PD to construct a predictive model for adverse prognoses using machine learning (ML). Methods: A retrospective analysis was conducted on 873 patients who underwent PD from August 2007 to December 2020. A total of 824 patients who met the inclusion criteria were included in the analysis. Five commonly used ML algorithms were used for the initial model training. By using the area under the curve (AUC) and accuracy (ACC), we ranked the indicators with the highest impact and displayed them using the values of Shapley additive explanation (SHAP) version 0.41.0. The top 20 indicators were selected to build a compact model that is conducive to clinical application. All model-building steps were implemented in Python 3.8.3. Results: At the end of follow-up, 353 patients withdrew from PD (converted to haemodialysis or died), and 471 patients continued receiving PD. In the complete model, the categorical boosting classifier (CatBoost) model exhibited the strongest performance (AUC = 0.80, 95% confidence interval [CI] = 0.76–0.83; ACC: 0.78, 95% CI = 0.72–0.83) and was selected for subsequent analysis. We reconstructed a compression model by extracting 20 key features ranked by the SHAP values, and the CatBoost model still showed the strongest performance (AUC = 0.79, ACC = 0.74). Conclusions: The CatBoost model, which was built using the intelligent analysis technology of ML, demonstrated the best predictive performance. Therefore, our developed prediction model has potential value in patient screening before PD and hierarchical management after PD.
- Open Access
- 20 September 2023
- Published by Springer Nature in Research Square
Machine-learning algorithms for the prediction of adverse prognosis in patients undergoing peritoneal dialysis
Background An appropriate prediction model for the adverse prognosis before peritoneal dialysis (PD) is lacking. Therefore, we retrospectively analyzed patients who received PD to construct a predictive model for adverse prognoses using machine learning (ML). Methods A retrospective analysis was conducted on 873 patients who underwent PD from August 2007 to December 2020. Five commonly used machine learning algorithms are used for initial model training. Using the area under the curve and accuracy, we ranked the indicators with the highest impact and displayed them using the Shapley additive explanation (version 0.41.0) values, from which the top 20 indicators were selected to build a compact model conducive to clinical application. All model building steps are implemented in Python (version 3.8.3). Results A total of 824 patients were included in the analysis at the end of follow-up, 353 patients withdrew from PD (converted to haemodialysis or died), and 471 patients continued receiving PD. In complete model, the CatBoost model exhibited the strongest performance (AUC: 0.80, 95% CI: 0.76–0.83; ACC: 0.78, 95%CI: 0.72–0.83) and was selected for subsequent analysis. We reconstructed a compression model by extracting 20 key features ranked by the SHAP values, the Catboost model also showed the strongest performance (AUC: 0.79; ACC: 0.74). Conclusions The Catboost model built using the intelligent analysis technology of ML demonstrated the best predictive performance. Thus, our developed prediction model has potential value in patient screening before PD and hierarchical management after peritoneal dialysis.
- 20 September 2023
- Published by Springer Nature in Research Square
Open AccessMachine-learning algorithms for the prediction of adverse prognosis in patients undergoing peritoneal dialysis
Background An appropriate prediction model for the adverse prognosis before peritoneal dialysis (PD) is lacking. Therefore, we retrospectively analyzed patients who received PD to construct a predictive model for adverse prognoses using machine learning (ML). Methods A retrospective analysis was conducted on 873 patients who underwent PD from August 2007 to December 2020. Five commonly used machine learning algorithms are used for initial model training. Using the area under the curve and accuracy, we ranked the indicators with the highest impact and displayed them using the Shapley additive explanation (version 0.41.0) values, from which the top 20 indicators were selected to build a compact model conducive to clinical application. All model building steps are implemented in Python (version 3.8.3). Results A total of 824 patients were included in the analysis at the end of follow-up, 353 patients withdrew from PD (converted to haemodialysis or died), and 471 patients continued receiving PD. In complete model, the CatBoost model exhibited the strongest performance (AUC: 0.80, 95% CI: 0.76–0.83; ACC: 0.78, 95%CI: 0.72–0.83) and was selected for subsequent analysis. We reconstructed a compression model by extracting 20 key features ranked by the SHAP values, the Catboost model also showed the strongest performance (AUC: 0.79; ACC: 0.74). Conclusions The Catboost model built using the intelligent analysis technology of ML demonstrated the best predictive performance. Thus, our developed prediction model has potential value in patient screening before PD and hierarchical management after peritoneal dialysis.
- Open Access
- 30 May 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 460-467
Relationship between Dialysate Bicarbonate Concentration and All-Cause Mortality in Hemodialysis Patients
Introduction: The optimal dialysate bicarbonate concentration (DBIC) for hemodialysis (HD) remains controversial. Herein, we analyzed the effect of dialysate bicarbonate levels on mortality in HD patients. Methods: Patients undergoing maintenance HD were recruited from the HD unit of the Daping Hospital. Patients were categorized into quartiles according to their DBIC level (quartile 1: <31.25 mmol/L, n = 77; quartile 2: 31.25–32.31 mmol/L, n = 76; quartile 3: 32.31–33.6 mmol/L; n = 81; quartile 4: ≥33.6 mmol/L, n = 79). Demographic and clinical data were collected. Survival curves were estimated using the Kaplan-Meier method. A Cox proportional hazards regression model was used to estimate the association between DBIC and all-cause mortality. Results: We included 313 patients undergoing maintenance HD with a mean DBIC of 32.16 ± 1.59 mmol/L (range, 27.20–34.72 mmol/L). The patients in quartile 4 were more likely to have higher pre- and post-HD serum bicarbonate concentrations than those in other quartiles. The mortality rate was lowest in quartile 2 (10.53%). The survival time was significantly lower in the quartile 4 group than in the other quartiles (p = 0. 008, log-rank test). After full adjustment, the hazard ratio (per 3 mmol/L higher DBIC) for all-cause mortality was 4.29 (95% confidence interval, 2.11–8.47) in all patients, whereas no significant association was observed between DBIC and initial hospitalization. Conclusions: Our data indicate that DBIC is positively associated with all-cause mortality. A DBIC concentration of 31–32 mmol/L may benefit patient outcomes. This study provides an evidence-based medical basis for optimal dialysis prescription in the future.
- 30 May 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 460-467
Open AccessRelationship between Dialysate Bicarbonate Concentration and All-Cause Mortality in Hemodialysis Patients
Introduction: The optimal dialysate bicarbonate concentration (DBIC) for hemodialysis (HD) remains controversial. Herein, we analyzed the effect of dialysate bicarbonate levels on mortality in HD patients. Methods: Patients undergoing maintenance HD were recruited from the HD unit of the Daping Hospital. Patients were categorized into quartiles according to their DBIC level (quartile 1: <31.25 mmol/L, n = 77; quartile 2: 31.25–32.31 mmol/L, n = 76; quartile 3: 32.31–33.6 mmol/L; n = 81; quartile 4: ≥33.6 mmol/L, n = 79). Demographic and clinical data were collected. Survival curves were estimated using the Kaplan-Meier method. A Cox proportional hazards regression model was used to estimate the association between DBIC and all-cause mortality. Results: We included 313 patients undergoing maintenance HD with a mean DBIC of 32.16 ± 1.59 mmol/L (range, 27.20–34.72 mmol/L). The patients in quartile 4 were more likely to have higher pre- and post-HD serum bicarbonate concentrations than those in other quartiles. The mortality rate was lowest in quartile 2 (10.53%). The survival time was significantly lower in the quartile 4 group than in the other quartiles (p = 0. 008, log-rank test). After full adjustment, the hazard ratio (per 3 mmol/L higher DBIC) for all-cause mortality was 4.29 (95% confidence interval, 2.11–8.47) in all patients, whereas no significant association was observed between DBIC and initial hospitalization. Conclusions: Our data indicate that DBIC is positively associated with all-cause mortality. A DBIC concentration of 31–32 mmol/L may benefit patient outcomes. This study provides an evidence-based medical basis for optimal dialysis prescription in the future.
- 1 April 2023
- Published by SAGE Publications in Stem Cells and Development
- Vol. 32 (7-8) , 197-211
Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Alleviate Peritoneal Dialysis-Associated Peritoneal Injury
Peritoneal fibrosis is a critical sequela that limits the application of peritoneal dialysis (PD). This study explored the role and mechanism of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) in preventing PD-associated peritoneal injury. C57BL/6 mice were randomized into three groups: a control (saline), peritoneal injury (2.5% glucose peritoneal dialysate + lipopolysaccharide (LPS)), and peritoneal injury + exosome group. After six weeks, mice were dissected, and the parietal peritoneum was collected. The level of peritoneal structural and functional damage was assessed. Additionally, transcriptome analysis of the peritoneum and miRNA sequencing on BMSC-Exos were performed. The parietal peritoneum had significantly thickened, and peritoneal function was impaired in the peritoneal injury group. Peritoneal structural and functional damage was significantly reduced after exosome treatment, while peritoneal inflammation, fibrosis, angiogenesis, and mesothelial damage significantly increased. Transcriptomic analysis showed that the BMSC-Exos affected the cell cycle process, cell differentiation, and inflammatory response regulation. Significant pathways in the exosome group were enriched by inflammation, immune response, and cell differentiation, which constitute a molecular network that regulates the peritoneal protective mechanism. Additionally, inflammatory factors (TNF-α, IL-1β), fibrosis markers (α-SMA, collagen-III, fibronectin), profibrotic cytokines (TGF-β1), and angiogenesis-related factor (VEGF) were downregulated at the mRNA and protein levels through BMSC-Exos treatment. BMSC-Exos treatment can prevent peritoneal injury by inhibiting peritoneal fibrosis, inflammation, and angiogenesis, showing a multi-target regulatory effect. Therefore, BMSC-Exos therapy might be a new therapeutic strategy for treating peritoneal injury.
- 1 April 2023
- Published by SAGE Publications in Stem Cells and Development
- Vol. 32 (7-8) , 197-211
Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Alleviate Peritoneal Dialysis-Associated Peritoneal Injury
Peritoneal fibrosis is a critical sequela that limits the application of peritoneal dialysis (PD). This study explored the role and mechanism of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) in preventing PD-associated peritoneal injury. C57BL/6 mice were randomized into three groups: a control (saline), peritoneal injury (2.5% glucose peritoneal dialysate + lipopolysaccharide (LPS)), and peritoneal injury + exosome group. After six weeks, mice were dissected, and the parietal peritoneum was collected. The level of peritoneal structural and functional damage was assessed. Additionally, transcriptome analysis of the peritoneum and miRNA sequencing on BMSC-Exos were performed. The parietal peritoneum had significantly thickened, and peritoneal function was impaired in the peritoneal injury group. Peritoneal structural and functional damage was significantly reduced after exosome treatment, while peritoneal inflammation, fibrosis, angiogenesis, and mesothelial damage significantly increased. Transcriptomic analysis showed that the BMSC-Exos affected the cell cycle process, cell differentiation, and inflammatory response regulation. Significant pathways in the exosome group were enriched by inflammation, immune response, and cell differentiation, which constitute a molecular network that regulates the peritoneal protective mechanism. Additionally, inflammatory factors (TNF-α, IL-1β), fibrosis markers (α-SMA, collagen-III, fibronectin), profibrotic cytokines (TGF-β1), and angiogenesis-related factor (VEGF) were downregulated at the mRNA and protein levels through BMSC-Exos treatment. BMSC-Exos treatment can prevent peritoneal injury by inhibiting peritoneal fibrosis, inflammation, and angiogenesis, showing a multi-target regulatory effect. Therefore, BMSC-Exos therapy might be a new therapeutic strategy for treating peritoneal injury.
- 12 August 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (9) , e22472
VNN1 contributes to the acute kidney injury–chronic kidney disease transition by promoting cellular senescence via affecting RB1 expression
The mechanisms underlying acute kidney injury (AKI) and chronic kidney disease (CKD) progression include interstitial inflammation, cellular senescence, and oxidative stress (OS). Although vanin‐1 (VNN1) plays an important role in OS, its contribution to the AKI‐CKD transition remains unknown. Here, we explored the roles and mechanisms of VNN1 in the progression of the AKI‐CKD transition. We observed that VNN1 expression was upregulated after ischemia/reperfusion (I/R) injury and high VNN1 expression levels were associated with poor renal repair after I/R injury. In VNN1 knockout (KO) mice, recovery of serum creatinine and blood urea nitrogen levels after I/R injury was accelerated and renal fibrosis was inhibited after severe I/R injury. Furthermore, in VNN1 KO mice, senescence of renal tubular cells was inhibited after severe I/R injury, as assessed by P16 expression and SA‐β‐Gal assays. However, our results also revealed that VNN1 KO renal tubular cells did not resist senescence when OS was blocked. To elucidate the mechanism underlying VNN1‐mediated regulation of senescence during the AKI‐CKD transition, retinoblastoma 1 (RB1) was identified as a potential target. Our results suggest that the reduced senescence in VNN1 KO renal tubular cells was caused by suppressed RB1 expression and phosphorylation. Collectively, our results unveil a novel molecular mechanism by which VNN1 promotes AKI‐CKD transition via inducing senescence of renal tubular cells by activating RB1 expression and phosphorylation after severe renal injury. The present study proposes a new strategy for designing therapies wherein VNN1 can be targeted to obstruct the AKI‐CKD transition.
- 12 August 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (9) , e22472
VNN1 contributes to the acute kidney injury–chronic kidney disease transition by promoting cellular senescence via affecting RB1 expression
The mechanisms underlying acute kidney injury (AKI) and chronic kidney disease (CKD) progression include interstitial inflammation, cellular senescence, and oxidative stress (OS). Although vanin‐1 (VNN1) plays an important role in OS, its contribution to the AKI‐CKD transition remains unknown. Here, we explored the roles and mechanisms of VNN1 in the progression of the AKI‐CKD transition. We observed that VNN1 expression was upregulated after ischemia/reperfusion (I/R) injury and high VNN1 expression levels were associated with poor renal repair after I/R injury. In VNN1 knockout (KO) mice, recovery of serum creatinine and blood urea nitrogen levels after I/R injury was accelerated and renal fibrosis was inhibited after severe I/R injury. Furthermore, in VNN1 KO mice, senescence of renal tubular cells was inhibited after severe I/R injury, as assessed by P16 expression and SA‐β‐Gal assays. However, our results also revealed that VNN1 KO renal tubular cells did not resist senescence when OS was blocked. To elucidate the mechanism underlying VNN1‐mediated regulation of senescence during the AKI‐CKD transition, retinoblastoma 1 (RB1) was identified as a potential target. Our results suggest that the reduced senescence in VNN1 KO renal tubular cells was caused by suppressed RB1 expression and phosphorylation. Collectively, our results unveil a novel molecular mechanism by which VNN1 promotes AKI‐CKD transition via inducing senescence of renal tubular cells by activating RB1 expression and phosphorylation after severe renal injury. The present study proposes a new strategy for designing therapies wherein VNN1 can be targeted to obstruct the AKI‐CKD transition.
- 30 March 2022
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 26 (7) , 649-658
Establishment of a novel mouse peritoneal dialysis-associated peritoneal injury model
Background Peritoneal fibrosis induced by various factors during peritoneal dialysis (PD) can eventually lead to ultrafiltration failure and termination of PD treatment. The existing animal models are caused by a single stimulus, and cannot accurately simulate complex pathogenesis of peritoneal injury and fibrosis. We aim to develop an efficient and realistic mouse model of PD-associated peritoneal injury using daily intraperitoneal injection (I.P.) of human peritonitis PD effluent. Methods Eight-week-old male C57BL/6 mice were classified into six groups: saline control; 2.5% PD fluid; 2.5% PD fluid + lipopolysaccharide (LPS); 4.25% PD fluid; 4.25% PD fluid + LPS; and peritonitis effluent. Mice received daily I.P. for 6 weeks, and were sacrificed to determine peritoneal structural and functional damage, inflammation, and fibrosis. Results Mice in the peritonitis effluent group had low mortality. The submesothelial thickness in the peritonitis effluent group was significantly greater than that in the 2.5% PD fluid group. The peritonitis effluent group had increased expression of fibrosis markers (α-SMA, Collagen I, etc.), neutrophil granulocytes (MPO), and macrophages (CD68, F4/80) in the peritoneum based on immunohistochemical staining; and significantly higher expression of inflammation markers (IL-1β, IL-6, etc.) and fibrosis markers (TGF-β1, α-SMA, etc.) based on real-time qPCR. Modified peritoneal equilibration tests (PET) demonstrated that I.P. of peritonitis effluent reduced peritoneal ultrafiltration. Conclusion Our novel animal model of PD-associated peritoneal injury faithfully simulates the clinical pathophysiological process. This animal model may be useful for study of the pathogenesis of PD-associated peritoneal injury and identification of novel treatments.
- 30 March 2022
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 26 (7) , 649-658
Establishment of a novel mouse peritoneal dialysis-associated peritoneal injury model
Background Peritoneal fibrosis induced by various factors during peritoneal dialysis (PD) can eventually lead to ultrafiltration failure and termination of PD treatment. The existing animal models are caused by a single stimulus, and cannot accurately simulate complex pathogenesis of peritoneal injury and fibrosis. We aim to develop an efficient and realistic mouse model of PD-associated peritoneal injury using daily intraperitoneal injection (I.P.) of human peritonitis PD effluent. Methods Eight-week-old male C57BL/6 mice were classified into six groups: saline control; 2.5% PD fluid; 2.5% PD fluid + lipopolysaccharide (LPS); 4.25% PD fluid; 4.25% PD fluid + LPS; and peritonitis effluent. Mice received daily I.P. for 6 weeks, and were sacrificed to determine peritoneal structural and functional damage, inflammation, and fibrosis. Results Mice in the peritonitis effluent group had low mortality. The submesothelial thickness in the peritonitis effluent group was significantly greater than that in the 2.5% PD fluid group. The peritonitis effluent group had increased expression of fibrosis markers (α-SMA, Collagen I, etc.), neutrophil granulocytes (MPO), and macrophages (CD68, F4/80) in the peritoneum based on immunohistochemical staining; and significantly higher expression of inflammation markers (IL-1β, IL-6, etc.) and fibrosis markers (TGF-β1, α-SMA, etc.) based on real-time qPCR. Modified peritoneal equilibration tests (PET) demonstrated that I.P. of peritonitis effluent reduced peritoneal ultrafiltration. Conclusion Our novel animal model of PD-associated peritoneal injury faithfully simulates the clinical pathophysiological process. This animal model may be useful for study of the pathogenesis of PD-associated peritoneal injury and identification of novel treatments.